TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q1 2026
Holdings as of Mar 31, 2026, filed May 15, 2026. Long positions only; changes compare share counts with Q4 2025.
- Positions
- 49
- +6 vs. Q4 2025
- Portfolio value
- $3.50B
- +$473.7M (+15.7%) vs. Q4 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ABVXAbivax S.A. | SPONSORED ADS | 6,481,085 | $721.7M | 20.6% | −630,511−8.9% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 3,670,206 | $248.4M | 7.1% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 10,531,071 | $220.3M | 6.3% | −2,231,023−17.5% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 4,946,894 | $190.4M | 5.4% | −921,268−15.7% | Reduced | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 4,286,480 | $170.3M | 4.9% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,676,624 | $140.7M | 4.0% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 3,248,980 | $124.4M | 3.6% | +350,877+12.1% | Added | History |
| IMVTImmunovant, Inc. | COM | 4,457,988 | $110.7M | 3.2% | +2,797,055+168.4% | Added | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 11,020,968 | $104.9M | 3.0% | +11,020,968 | New | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 1,062,049 | $98.1M | 2.8% | +1,000,000+1,611.6% | Added | History |
| VORVor Biopharma Inc. | COM NEW | 5,673,078 | $96.5M | 2.8% | +5,673,078 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,900,582 | $95.9M | 2.7% | 00.0% | Unchanged | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 6,243,812 | $86.8M | 2.5% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 1,341,862 | $85.8M | 2.5% | +1,341,862 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 4,615,144 | $83.7M | 2.4% | 00.0% | Unchanged | History |
| GLUEMonte Rosa Therapeutics, Inc. | COM | 4,622,151 | $76.0M | 2.2% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 12,362,205 | $67.5M | 1.9% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 576,473 | $56.1M | 1.6% | +140,000+32.1% | Added | History |
| KODKodiak Sciences Inc. | COM | 1,445,538 | $55.1M | 1.6% | 00.0% | Unchanged | History |
| LBRXLB Pharmaceuticals Inc | COM SHS | 1,839,489 | $45.3M | 1.3% | +94,474+5.4% | Added | History |
| SRZNSurrozen, Inc. | COM NEW | 1,473,101 | $42.9M | 1.2% | +1,473,101 | New | History |
| ADCTADC Therapeutics SA | SHS | 11,390,175 | $42.7M | 1.2% | 00.0% | Unchanged | History |
| RLAYRelay Therapeutics, Inc. | COM | 4,273,356 | $42.5M | 1.2% | +1,053,170+32.7% | Added | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,250,000 | $40.3M | 1.2% | 00.0% | Unchanged | History |
| BHVNBiohaven Ltd. | COM | 4,631,317 | $39.2M | 1.1% | 00.0% | Unchanged | History |
| IPSCCentury Therapeutics, Inc. | COM | 17,754,430 | $39.0M | 1.1% | +17,754,430 | New | History |
| TECXTectonic Therapeutic, Inc. | COM | 1,204,891 | $37.2M | 1.1% | +1,204,891 | New | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 7,915,567 | $33.0M | 0.9% | +7,915,567 | New | History |
| XNCRXencor Inc | COM | 2,452,138 | $29.6M | 0.8% | 00.0% | Unchanged | History |
| TRDAEntrada Therapeutics, Inc. | COM | 2,287,500 | $28.9M | 0.8% | +199,108+9.5% | Added | History |
| ALXOAlx Oncology Holdings Inc | COM | 13,011,849 | $26.1M | 0.7% | +13,011,849 | New | History |
| ARVNArvinas, Inc. | COM | 2,387,461 | $25.3M | 0.7% | −278,755−10.5% | Reduced | History |
| JANXJanux Therapeutics, Inc. | COM | 1,789,617 | $24.9M | 0.7% | 00.0% | Unchanged | History |
| AGMBAgomAb Therapeutics NV | SPONSORED ADS | 2,053,233 | $21.5M | 0.6% | +2,053,233 | New | History |
| ALECAlector, Inc. | COM | 10,000,000 | $21.5M | 0.6% | 00.0% | Unchanged | History |
| MBXMBX Biosciences, Inc. | COM | 650,000 | $19.4M | 0.6% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 3,033,560 | $16.0M | 0.5% | 00.0% | Unchanged | History |
| LQDALiquidia Corp | COM NEW | 403,048 | $15.2M | 0.4% | −1,307,036−76.4% | Reduced | History |
| OCULOcular Therapeutix, Inc | COM | 1,647,752 | $14.0M | 0.4% | −4,092,479−71.3% | Reduced | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 738,383 | $11.0M | 0.3% | +255,383+52.9% | Added | History |
| URGNUroGen Pharma Ltd. | COM | 405,365 | $7.29M | 0.2% | −311,982−43.5% | Reduced | History |
| MNPRMonopar Therapeutics | COM NEW | 132,103 | $7.24M | 0.2% | −9,812−6.9% | Reduced | History |
| CNTXContext Therapeutics Inc. | COM | 2,682,696 | $7.03M | 0.2% | +2,682,696 | New | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 140,411 | $6.77M | 0.2% | −780,446−84.8% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 406,786 | $5.78M | 0.2% | +406,786 | New | History |
| KRROKorro Bio, Inc. | COM | 416,301 | $4.71M | 0.1% | 00.0% | Unchanged | History |
| LONALeonaBio, Inc. | COM | 464,398 | $4.67M | 0.1% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 181,063 | $1.63M | <0.1% | −562,823−75.7% | Reduced | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,676,580 | $1.53M | <0.1% | 00.0% | Unchanged | History |
Sold out since Q4 2025 (5)
Positions held at the end of Q4 2025 that are gone from this filing.
| Security | Class | Shares in Q4 2025 | Value in Q4 2025 | % of portfolio in Q4 2025 | History |
|---|---|---|---|---|---|
| RAPTRAPT Therapeutics, Inc. | COM NEW | 2,582,408 | $87.5M | 2.9% | History |
| EYPTEyePoint, Inc. | COM NEW | 3,572,335 | $65.3M | 2.2% | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 1,181,841 | $32.2M | 1.1% | History |
| MAZEMaze Therapeutics, Inc. | COM | 173,816 | $7.20M | 0.2% | History |
| VTYXVentyx Biosciences, Inc. | COM | 316,195 | $2.86M | 0.1% | History |